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THIS study was undertaken to investigate the correla-
tion between the serum ECP and the serum eotaxin
level, and disease activity as evaluated with pulmo-
nary  function  in  patients  with  asthma  or  chronic
obstructive  pulmonary  disease  (COPD).  20  patients
with stable asthma and 15 patients with COPD, and 15
subjects of the control group took part in this study.
The analysis of ECP was performed according to the
manufacturer’s  directions  (Pharmacia  Diagnostics
AB,  Uppsala,  Sweden ).  The  ELISA  test  was  used  to
measure  eotaxin  levels  in  sserum  (kits  from  R&D,
USA). The levels of ECP were 16.9±6.3 m g/L in patients
with asthma, 15.1±9.3 m g/L in patients with COPD and
11.8±6.2 m g/L  in  the  control  group  (P<0.05).  There
was no significant difference in the asthma ECP level
compared with the ECP level in COPD. There was a
significant difference between the ECP plasma level
in asthma compared with the ECP plasma level in the
control  group  (p<0.05).  The  levels  of  eotaxin  were
175.8±49.3 pg/mL in the control group. There was a
correlation of  ECP and the eotaxin level in asthma
patients (r=+0.5, p<0.05). The percentage fall in FEV1
correlated  with  eotaxin  level  in  asthma  (r=–0.3,
p<0.05) and with the eotaxin level in COPD (r=–0.5,
p<0.05). Serum outcomes of eotaxin and ECP levels
appear to be a useful indicator of atopic asthma, and
might provide complementary data disease monitor-
ing. Therefore, further investigations are required to
clarify whether serum eotaxin measurements have a
role in the clinical evaluation in COPD.
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Introduction
Asthma and chronic obstructive pulmonary diseases
are  a  complex  of  conditions,  which  have  airflow
limitation in  common.1 The most characteristic fea-
tures of asthma are short-term changes in the airway
caliber, reversible airflow limitation, bronchial hyper-
responsiveness as well as eosinophilic and lympho-
cytic airway inflammation. The common definition of
COPD implies  long-term changes  in  airway  caliber,
less or irreversible airflow obstruction, seldom or no
bronchial hyperresponsiveness and neutrophilic air-
way  inflammation.  Some  studies  have  suggested  a
pathogenic role for airway inflammation in inducing
hypersecretion of mucus, lung destruction and airway
obstruction.
Eosinophils  are  believed  to  be  critical  proin-
flammatory  cells  in  airways  mucosal  damage  in
asthma  by  releasing  highly  toxic  proteins.  One  of
these proteins, eosinophil cationic protein (ECP), can
be quantitated in bronchial secretion and peripheral
blood.  Serum  ECP  levels  have  been  found  to  be
correlated  with  the  severity  of  asthma,2 exercise-
induced  bronchoconstriction3 and  allergen  expo-
sure.4 It  has been  found  that ECP  can  be  used  to
monitor asthma inflammation5 and may be a useful
marker in selecting allergic patients with eosinophil
related activation to allergen exposure.6 Setta et al.
however,  found  that the  numbers  of tissue  eosino-
phils are markedly and significantly increased when
there  is  an  exacerbation  of  bronchitis,  and  that
associated with the exacerbation their numbers are
similar  to  those  reported  in  stable  asthma.7 An
increased level of ECP was observed in the sputum
and bronchial lavage from patients with COPD.8,9
Several  chemokines  of  the  CC  family,  including
eotaxin,  RANTES,  monocyte chemotactic protein  3
(MCP-3) and MCP-4 have been shown to attract and
activate  eosinophils  via  high  affinity  binding  to
CCR3.10,11 However, only eotaxin binds selectively to
this receptor, which supposedly explains why eotaxin
is relatively selective in eosinophil recruitment.12
The CC chemokine eotaxin is a potent and selective
chemoattractant, which signals via the CCR3 recep-
tor. It has been found to be a potent chemoattractant
for  human  eosinophils  and  basophils  as  well  as  a
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zation, actin reorganization, and CD11b up-regulation
for human eosinophils.13,14The human eotaxin recep-
tor, CCR3, is expressed on eosinophils, basophils, and
TH2 cells.15 Eotaxin, in association with TH1-derived
cytokine  IL-2  and TH2-derived  cytokine  IL-4,  is  an
important  T  lymphocyte  activator,  stimulating  the
directional  migration,  adhesion,  accumulation,  and
recruitment  of T  lymphocytes,  in  parallel  with  the
accumulation of eosinophils and basophils during the
process  of  certain  types  of  inflammation  such  as
allergy. The synergism between remotely acting IL-5
and locally acting eotaxin will induce a rapid recruit-
ment  of  eosinophils  in  the  allergen-stimulated  tis-
sue.16 To our knowledge, there is no known role of
this chemokine in the pathomechanism of asthma and
COPD.
The  aim  of  this  study  was  to  investigate  the
correlation between the serum  ECP,  serum  eotaxin
level and disease activity as evaluated with pulmonary
function in patients with asthma or COPD.
Material and methods
20 patients (11 women and 9 men; mean age 27.7 ±
4.8) with asthma, 15 (6 women and 11 men, mean age
60.9 ± 8.1) with COPD and 15 subjects (8 women and
7 men, mean age 36.8 ± 10.5) from the control group
took part in this study.
The  patients  with  asthma  showed  the  following
characteristics: one or more positive skin weal-and-
flare response to skin prick testing with a range of
local allergens, history indicating several episodes of
bronchoconstriction over a period of at least 2 years,
and in  relation to the exposure to one or more of
those allergens, reversible airflow obstruction with a
> 20% increase in the forced expiratory volume 1s
(FEV1)  after  inhaled  b2-receptor  agonists  (400mg
salbutamol) and airway hyperresponsiveness, as dem-
onstrated by a cumulative histamine provocation dose
causing  a  100%  increase  in  expiratory  resistance
(PD100Raw) on more than one occasion during the
previous 30 days. None of the tested patients was a
current  smoker.  They  were  stable  at  the  time  of
testing, requiring only intermittent use of short-acting
b2  receptor agonists. The subjects with COPD had
not  been  hospitalized  for  the  exacerbation  of  the
illness and met the following criteria: chronic sputum
production, cough,  low  FEV1/VC  ratio,  increase in
FEV1  following  inhaled  b2-agonist  of  <12%,  no
history of seasonal or episodic dyspnea, wheezing or
atopy,  current  cigarette  smoking  without  occupa-
tional  or  other  exposure  known  to  cause  chronic
bronchitis,  and  no  therapy  with  oral  or  inhaled
glucocorticosteroids within  3  months of  entry into
the study. All of the control subjects were lifelong non-
smokers, with normal spirometry and with no history
of atopy.
Each study subject had pulmonary function studies
including vital capacity, forced expiratory volume in
1s (FEV1), forced expiratory flow at 50% (FEF50) and
expiratory  resistance  (Raw).  Spirometry  was  per-
formed  with  Pneumoscreen  equipment  between
08:00 and 09:00 am.
Blood  drawing,  handling  and  storage  were  per-
formed by the same researcher in the same depart-
ment.  No  significant  variation  in  temperature  was
observed between the room where blood was drawn
and the laboratory where the preparation and storage
of  the  serum  took place. The  blood  samples  were
centrifuged at 1300 ´ g at 4°C for 10min, stored at
–70°C  until  measurements  of  the  ECP  and  eotaxin
were  taken.  The  analysis  of  ECP  was  performed
according to the manufacturer’s directions (Pharma-
cia Diagnostics AB, Uppsala, Sweden). The detection
limit of this kit is 2.0mg/L. The analysis was performed
blindly and each sample measurement was performed
in duplicate.
An ELISA system sensitive enough to detect 5pg/ml
of  human  eotaxin  was  used  to  determine  eotaxin
serum level (kits from R&D, USA). The variation in the
measured  eotaxin  levels  was  always  less  than  3%
when samples were analyzed in duplicate on an ELISA
plate.
The study was approved by the ethics committee of
our  hospital,  and  written  informed  consent  was
obtained from all participating subjects.
Statistical analysis
Statistical analysis of the data was performed by the
SPSS Window  5.0  statistics  program.  Results  were
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Table 1. FEVl (% predicted, mean±SD)
FEV1 before salbutamol FEV1 after salbutamol
Asthma (n=20) 67.9±6.3 (57–80) 90.2±6.6 (55–70)
COPD (n=15) 63.9±5.1 (55–70) 68.9±3.6 (62–75)
Normal controls (n=15) 90±6.3 (78–100) Not done
Statistical significance Asthma vs. COPD, p=0.05 Asthma vs. COPD, p<0.0001
Asthma vs. control, p<0.0001
COPD vs. control, p<0.0001expressed  as  mean  ±  SD.  Correlations among  vari-
ables were determined with an analysis to give the
Pearson’s rank correlation coefficient. A p value of less
than 0.05 was considered significant.
Results
The mean levels of expired volumes after 1s (FEV1)
are shown in Table 1. FEV1 was significantly reduced
in patients with asthma and COPD compared to the
control group (p<0.05). All of the patients studied had
detectable levels of plasma ECP and eotaxin.
The levels of ECP were 16.9±6.3mg/L in patients
with asthma, 15.1±9.3mg/L in  patients with COPD
and 11.8±6.2mg/L in the control group (p<0.05) (Fig.
1). There was no significant difference in the asthma
ECP  level  compared  with  the  ECP  level  in  COPD.
There was a significant difference between the ECP
plasma level in asthma compared to the ECP plasma
level in the control group (p<0.05).
The  levels  of  eotaxin  were  175.8±49.3pg/mL  in
asthma  patients,  286.0±101.4pg/mL  in  COPD
patients and 109.6±56.1pg/mL in the control group
(Fig.  2).  There  were  significant  differences  in  the
asthma  eotaxin  level  as  compared  to  COPD
Eotaxin in asthma or COPD
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FIG. 1. Serum ECP (mg/L) in asthma, COPD, and controls.
FIG. 2. Serum eotaxin (pg/mL) in asthma, COPD and controls.(p<0.0001), asthma as compared to the control group
(p<0.0001),  and COPD as compared to the control
group (p<0.0001).
There was correlation of the ECP and the eotaxin
level in asthma patients (r=+0.5, p<0.05) (Fig. 3). The
percentage fall in FEV1  correlated with the eotaxin
level in asthma (r=–0.3, p<0.05). There was correla-
tion of the percentage fall in FEV1 with the eotaxin
level in COPD (r=–0.5, p<0.05).
Discussion
To  our  knowledge,  this  is  the  first  time  that  an
increase  of  eotaxin  and  ECP  levels  in  serum  of
patients  with  asthma  and  COPD  as  well  has  been
demonstrated.  The  study  documented  that  serum
eotaxin  levels  were  significantly  higher  in  COPD
patients than in asthma patients and control subjects.
Morever,  the  current  investigation  has  shown  that
serum eotaxin levels are inversely related to the lung
function  (FEV1)  in  patients  with  asthma or  COPD.
However,  only  in  asthma  patients  was  significant
correlation between ECP and eotaxin levels found.
The ELISA test is an accurate and useful method for
quantifying  human  eotaxin  in  the  blood,  but  the
process  of  preparing  blood  samples  affects  the
measurement of eotaxin levels.17 The previous study
(Ref. 17) demonstrated that eotaxin levels in serum
samples  were  significantly  higher  than  those  in
matched plasma  samples separated from  the  blood
collected in tubes containing EDTA.
Since the serum measurement of ECP is relatively
easy to perform and non-invasive, the usefulness  of
serum ECP as a clinical marker in asthma has recently
been  studied.6,18 The  serum  ECP  level  has  been
shown  to  be  correlated  with  all  the  indices  of
eosinophilic inflammation or asthma activity, suggest-
ing that serum ECP might be a very useful marker in
the disease.18 In asthmatic patients, the serum ECP
level  demonstrated correlation with the number or
percentage  of  eosinophils  in  BALF,  and  tissue,
whereas the blood eosinophil count correlated only
with the percentage of eosinophils in BALF. Our study
showed that the serum level of ECP correlated with
the elevated serum level of eotaxin. Elevated levels of
eotaxin protein and mRNA have been demonstrated
in the airways of asthmatic patients at baseline19 and
after  allergen  inhalation.20 Moreover,  eotaxin  level
and  eosinophils  increased  at  the  onset  of  a  viral
respiratory infection  in  guinea  pig  bronchoalveolar
lavage.21 Lilly et al.found higher plasma eotaxin levels
in patients with acute asthma.22 Acutely ill asthmatic
subjects  who  did  not  respond  to  an  emergency
treatment had higher eotaxin levels  than did those
admitted to hospital or those discharged home. To our
knowledge  no  studies  have  been  conducted  to
investigate serum eotaxin levels in COPD patients. No
study  has  also  been  performed  on  the  correlation
between the serum ECP level and the serum eotaxin
level in COPD. Interestingly, the increase of eosino-
phils in the exacerbation of bronchitis is reported not
to  be  accompanied by  increases in  the  number  of
inflammatory cells showing immunoreactivity for IL-5
protein.23 Zhu  et  al.  (unpublished)  have,  however,
recently found that airways resected from smokers’
lungs do demonstrate marked gene expression for IL-4
and IL-5, and that is, in particular, associated with the
bronchial  glands  of  subjects  with  chronic  hyper-
secretion. The observation of the occurrence of both
IL-4  and  IL-5  gene  expression  in  COPD,  questions
further the distinctions between asthma and COPD
and  presents  us  with  a  new  challenge  for  further
K. Jahnz-R´ o` zyk et al.
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FIG. 3. Relationship between ECP and eotaxin levels in asthma patients. Corr. coeff. = +0.5.research.  In  conclusion,  we  found  a  significantly
higher  serum  eotaxin  level  in  patients  with  COPD
compared  to  patients  with  asthma.  However,  the
outcomes of serum eotaxin and ECP levels appear to
be  a  useful  indicator  of  atopic  asthma,  and  might
provide complementary data in disease monitoring.
Further  longitudinal  investigations  should  establish
the role of measuring serum eotaxin in the clinical
evaluation and monitoring of asthma, in particular, of
COPD patients.
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